Operating With Scientific Rigor: How Brennan Changed Cancer Surgery
Sir Murray F. Brennan, MD, made his reputation—and saved many lives—by pioneering the use of rigorous empirical analysis to evaluate alternative strategies and optimize outcomes in surgical oncology.
Network Enlists Practicing Oncologists to Develop Plans
Physicians are carefully evaluating potential partnership and referral deals to ensure that whatever they do is perceived as aligned with delivering better, more efficient care.
Combos May Extend Reach of CDK4/6 Inhibitors in Breast Cancer
Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.
New Criteria Needed to Evaluate Immunotherapy Responses
Most patients who appear to progress after they begin receiving anticancer immunotherapy will never exhibit a response to therapy.
Keeping a Tight Rein on Unnecessary Expenditures in Oncology Practice
Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.
Effective Management of CINV Improves Response to Treatment
The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.
Moving Forward in Head and Neck Squamous Cell Cancer
Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.
Novel Antibody Tested in First-Line DLBCL Therapy
Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
Microbiome Emerges as a Hot Topic in Cancer Research
Researchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.
Beyond CARs: New T-Cell Strategies Take Center Stage
Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.
Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer
Pancreatic ductal adenocarcinoma, which is considered incurable, accounts for more than 90% of pancreatic cancer cases.
Proving "Noninferiority" May Become Another Challenge in Oncology Studies
Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.